Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up

• 出版年: Clinical, Cosmetic and Investigational Dermatology
• 主要な著者: Song B, Liu X, Jin H
• フォーマット: 論文
• 言語: 英語
• 出版事項: Dove Medical Press 2024-08-01
• 主題: erythrodermic psoriasis; alopecia; ixekizumab
• オンライン･アクセス: https://www.dovepress.com/ixekizumab-improved-refractory-erythrodermic-psoriasis-with-comorbid-d-peer-reviewed-fulltext-article-CCID

Biao Song,1– 3,* Xiaohan Liu,1– 3,* Hongzhong Jin1– 3 1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of China; 2State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, People’s Republic of China; 3National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hongzhong Jin, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of China, Email [e-mail]: Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis, accounting for less than 3% of cases. It is characterized by widespread scaling and erythema that affects more than 90% of the body surface area. Alopecia can manifest as a symptom associated with the disease, further exacerbating the impact on the patient’s quality of life. We present the case of a patient with severe EP and diffuse alopecia who did not respond to conventional therapies. The patient was subsequently treated with ixekizumab as per labeled usage, resulting in complete resolution of both psoriatic skin lesions (Psoriasis area and severity index/PASI 100) and alopecia (The Severity of Alopecia Tool/SALT 0).Keywords: erythrodermic psoriasis, alopecia, ixekizumab